Peer-influenced content. Sources you trust. No registration required. This is HCN.

Journal of Clinical OncologyPoly(ADP-Ribose) Polymerase (PARP) Inhibitors in the Management of Ovarian Cancer: ASCO Guideline Rapid Recommendation Update

This update is based on the results from the June 2022 ATHENA-MONO2 phase III multinational, double-blind, randomized controlled trial (RCT), which showed a significant improvement in progression-free survival (PFS) in patients with stage III-IV epithelial ovarian cancer (EOC) who are in complete or partial response to first-line platinum-based chemotherapy.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form